Manufacturer of Controlled Substances; Notice of Registration, 76756 [2010-30904]

Download as PDF 76756 Federal Register / Vol. 75, No. 236 / Thursday, December 9, 2010 / Notices of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: November 29, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 29, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–30897 Filed 12–8–10; 8:45 am] BILLING CODE 4410–09–P [FR Doc. 2010–30904 Filed 12–8–10; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Registration Drug Enforcement Administration By Notice dated July 19, 2010, and published in the Federal Register on July 28, 2010, (75 FR 44285), Johnson Matthey Pharmaceutical Materials, Inc., Pharmaceuticals Service, 25 Patton Road, Devens, Massachusetts 01434, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances: Drug Manufacturer of Controlled Substances; Notice of Registration By Notice dated March 16, 2010, and published in the Federal Register on March 24, 2010, (75 FR 14189), Norac Inc., 405 S. Motor Avenue, P.O. Box 577, Azusa, California 91702–3232, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances: Schedule Drug erowe on DSK5CLS3C1PROD with NOTICES Amphetamine (1100) .................... Methylphenidate (1724) ................ Nabilone (7379) ............................ Alfentanil (9737) ........................... Sufentanil (9740) .......................... Remifentanil (9739) ...................... Hydrocodone (9193) ..................... II II II II II II II Gamma Hydroxybutyric Acid (2010). Tetrahydrocannabinols (7370) ..... Methamphetamine (1105) ............ Nabilone (7379) ............................ The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company’s primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company’s customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Pharmaceutical Materials, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey Pharmaceutical Materials, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included VerDate Mar<15>2010 15:35 Dec 08, 2010 Jkt 223001 Schedule I I II II With regard to Gamma Hydroxybutyric Acid (2010), Tetrahydrocannabinols (7370), and Methamphetamine (1105) only, the company manufactures these controlled substances in bulk solely for domestic distribution within the United States to customers engaged in dosage-form manufacturing. With regard to Nabilone (7379) only, the company presently manufactures a small amount of this controlled substance in bulk solely to conduct manufacturing process development internally within the company. It is the company’s intention that, when the manufacturing process is refined to the point that its Nabilone bulk product is available for commercial use, the company will export the controlled substance in bulk solely to customers engaged in dosage-form manufacturing outside the United States. The company is aware of the requirement to obtain a PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 DEA registration as an exporter to conduct this activity. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Norac, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Norac, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: November 29, 2010. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2010–30903 Filed 12–8–10; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated July 23, 2010, and published in the Federal Register on August 4, 2010, (75 FR 47029), Johnson Matthey Pharma Services, 70 Flagship Drive, North Andover, Massachusetts 01845, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances: Drug Amphetamine (1100) .................... Methylphenidate (1724) ................ Hydrocodone (9193) ..................... Schedule II II II The company plans to utilize this facility to manufacture small quantities of the listed controlled substances in bulk and to conduct analytical testing in support of the company’s primary manufacturing facility in West Deptford, New Jersey. The controlled substances manufactured in bulk at this facility will be distributed to the company’s customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and E:\FR\FM\09DEN1.SGM 09DEN1

Agencies

[Federal Register Volume 75, Number 236 (Thursday, December 9, 2010)]
[Notices]
[Page 76756]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-30904]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated July 19, 2010, and published in the Federal 
Register on July 28, 2010, (75 FR 44285), Johnson Matthey 
Pharmaceutical Materials, Inc., Pharmaceuticals Service, 25 Patton 
Road, Devens, Massachusetts 01434, made application by letter to the 
Drug Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Amphetamine (1100).........................  II
Methylphenidate (1724).....................  II
Nabilone (7379)............................  II
Alfentanil (9737)..........................  II
Sufentanil (9740)..........................  II
Remifentanil (9739)........................  II
Hydrocodone (9193).........................  II
------------------------------------------------------------------------

    The company plans to utilize this facility to manufacture small 
quantities of the listed controlled substances in bulk and to conduct 
analytical testing in support of the company's primary manufacturing 
facility in West Deptford, New Jersey. The controlled substances 
manufactured in bulk at this facility will be distributed to the 
company's customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Johnson Matthey Pharmaceutical Materials, Inc. to manufacture the 
listed basic classes of controlled substances is consistent with the 
public interest at this time. DEA has investigated Johnson Matthey 
Pharmaceutical Materials, Inc. to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems, verification of the company's compliance with state and local 
laws, and a review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, 
the above named company is granted registration as a bulk manufacturer 
of the basic classes of controlled substances listed.

    Dated: November 29, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2010-30904 Filed 12-8-10; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.